CHICAGO, IL / ACCESSWIRE / July 2, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has enhanced and expanded its strategic collaboration with C.A. Papaellinas Group ("Papaellinas") and provided an update on the number of units sold since inception in Cyprus, as well as a projection of incremental units to be sold by the end of 2024.

As communicated on September 20, 2023, Cosmos Health entered into a strategic collaboration with Papaellinas to represent and distribute Sky Premium Life products in Holland & Barrett stores and pharmacies throughout Cyprus. To date, 68,000 units have been sold, and given the positive market reception, there is an increased effort to expand reach.

Consequently, the Company has enhanced and expanded its collaboration with Papaellinas and anticipates a rise in the rate of units sold, with sales expected to more than double to exceed 150,000 units within the following twelve months due to, among other factors, increased penetration in pharmacies across Cyprus. Moreover, the Company is exploring additional opportunities to expand its collaboration with Papaellinas beyond Sky Premium Life products.

Founded in 1929, Papaellinas is a leading importer and distributor of beauty, pharmaceutical, and consumer products in Cyprus. They represent a diverse array of brands, including Panadol, Sensodyne, and Kleenex, as well as Adidas, Chanel, and Hermes. The company also operates several retail chains in Cyprus, such as Beauty Line, Holland & Barrett, Yves Rocher, and Butterfly Beauty Store. The Group boasts an annual turnover of over €200 million and employs more than 600 individuals.

Greg Siokas, CEO of Cosmos Health, stated: "We are extremely pleased with the sales performance of our Sky Premium Life products in Cyprus. Our collaboration with Papaellinas has been outstanding, and we couldn't ask for a better partner. We look forward to generating additional momentum and gaining market share."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+44 207 0971 653